Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors
Status:
Completed
Trial end date:
2003-03-01
Target enrollment:
Participant gender:
Summary
Phase I trial to study the effectiveness of tributyrin in treating patients with refractory
stage IV prostate cancer or other solid tumors. Drugs used in chemotherapy use different ways
to stop tumor cells from dividing so they stop growing or die.
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Institute (NCI) University of Maryland, Baltimore